10/29
08:08 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $65.00 price target on the stock.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $65.00 price target on the stock.
9/30
10:12 am
supn
Rating for SUPN
Low
Report
Rating for SUPN